These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15659517)

  • 1. Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan.
    Kramar A; Gourgou-Bourgade S; Ychou M
    J Clin Oncol; 2005 Jan; 23(3):650; author reply 650-1. PubMed ID: 15659517
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.
    Meyerhardt JA; Kwok A; Ratain MJ; McGovren JP; Fuchs CS
    J Clin Oncol; 2004 Apr; 22(8):1439-46. PubMed ID: 15084617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
    Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
    Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship between UGT1A and irinotecan-related toxicity].
    Xu JM
    Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):241-3. PubMed ID: 23985249
    [No Abstract]   [Full Text] [Related]  

  • 5. Colorectal cancer: dilemmas regarding patient selection and toxicity prediction.
    Nikolic-Tomasevic Z; Jelic S; Popov I; Radosavljevic D
    J Chemother; 2000 Jun; 12(3):244-51. PubMed ID: 10877521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan for metastatic colorectal cancer.
    Med Lett Drugs Ther; 1997 Jan; 39(992):8. PubMed ID: 9008684
    [No Abstract]   [Full Text] [Related]  

  • 7. The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients.
    Yumuk PF; Aydin SZ; Dane F; Gumus M; Ekenel M; Aliustaoglu M; Karamanoglu A; Sengoz M; Turhal SN
    Int J Colorectal Dis; 2004 Nov; 19(6):609-10. PubMed ID: 15293062
    [No Abstract]   [Full Text] [Related]  

  • 8. Irinotecan: a new antineoplastic agent for the management of colorectal cancer.
    Cersosimo RJ
    Ann Pharmacother; 1998 Dec; 32(12):1324-33. PubMed ID: 9876815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer.
    Paulík A; Grim J; Filip S
    Acta Medica (Hradec Kralove); 2012; 55(4):153-9. PubMed ID: 23631285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan in the first-line treatment of colorectal cancer.
    Saltz LB
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):54-8. PubMed ID: 9726092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CPT-11: new drug for metastatic colorectal cancer].
    Barone C; Pozzo C; Cassano A
    Tumori; 1999; 85(6):A1-11. PubMed ID: 10774581
    [No Abstract]   [Full Text] [Related]  

  • 12. [[Irinotecan--experience with second-line treatment in advanced colorectal cancer] ].
    Kristó K; Izsó J; Balatoni G; Lohinszky J; Farczádi E; Szántó J; Kofi AP; Pintér T
    Orv Hetil; 2000 Aug; 141(33):1817-20. PubMed ID: 10979311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-agent irinotecan for recurrent/metastatic colorectal cancer: a retrospective analysis.
    Sanli UA; Karabulut B; Uslu R; Korkut M; Goker E
    Med Princ Pract; 2006; 15(4):288-92. PubMed ID: 16763396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA approves irinotecan as first-line therapy for colorectal cancer.
    Oncology (Williston Park); 2000 May; 14(5):652, 654. PubMed ID: 10853457
    [No Abstract]   [Full Text] [Related]  

  • 15. Moving beyond fluorouracil for colorectal cancer.
    Mayer RJ
    N Engl J Med; 2000 Sep; 343(13):963-4. PubMed ID: 11006373
    [No Abstract]   [Full Text] [Related]  

  • 16. Irinotecan: toward clinical end points in drug development.
    Pazdur R
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):13-21. PubMed ID: 9726086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
    Price T; Hill M
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):28-31. PubMed ID: 11098487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-treatment serum total bilirubin level as an indicator of optimal CPT-11 dosage.
    Makihara K; Azuma S; Kawato N; Ueno H; Nakata I
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):273-9. PubMed ID: 25432775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
    Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
    Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
    Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
    Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.